Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors

International Journal of Oncology

Volumn 30, Issue 5, 2007, Pages 1163-1171

  Uchida, Makiko ^a   Iwase, Masayasu ^a   Takaoka, Sayaka ^a   Yoshiba, Sayaka ^a   Kondo, Gen ^a   Watanabe, Hitoshi ^a   Ohashi, Masaru ^a   Nagumo, Masao ^a   Shintani, Satoru ^a  

^a SHOWA UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

Author keywords

Apoptosis; Cellular FLICE inhibitory protein; Phosphatidylinositol 3 kinase Akt; Squamous cell carcinoma; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

DNA FRAGMENT; ENZYME INHIBITOR; LIGAND; PHOSPHATIDYLINOSITOL 3 KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL MEMBRANE POTENTIAL; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MITOCHONDRION; MOUTH TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA FRAGMENTATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MEMBRANE POTENTIALS; MITOCHONDRIA; MOUTH NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 34447303860     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.5.1163     Document Type: Article

References (56)

1. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 1995: 673-682, 1995.
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690, 1996. (Pubitemid 26175834)
3. Green DR: Apoptotic pathways: paper wraps stone blunts scissors. Cell 102: 1-4, 2000.
4. Ashkenazi A: Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat Rev Cancer 2: 420-430, 2002.
5. Younes A and Kadin ME: Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 21: 3526-3534, 2003.
6. Kondo K, Yamasaki S, Sugie T, et al: Cisplatin-dependent upregulation of death receptor 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma. Int J Cancer 118: 230-242, 2006.
7. Lawrence D, Shahrokh Z, Marsters S, et al: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7: 383-385, 2001.
8. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM and Jeremias I: TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NFκB. Oncogene 22: 3842-3852, 2003.
9. Jarpe MB, Widmann C, Knall C, et al: Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. Oncogene 17: 1475-1482, 1998.
10. Irmler M, Thome M, Hahne M, et al: Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195, 1997.
11. Chao DT and Korsmeyer SJ: BCL-2 family: regulators of cell death. Annu Rev Immunol 16: 395-419, 1998.
12. Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin AS: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998.
13. Yagita H, Takeda K, Hayakawa Y, Smyth MJ and Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95: 777-783, 2004.
14. Sheridan JP, Marsters SA, Pitti RM, et al: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821, 1997.
15. Lee SH, Shin MS, Kim HS, et al: Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 20: 399-403, 2001.
16. Deng Y, Lin Y and Wu X: TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 16: 33-45, 2002.
17. Leverkus M, Sprick MR, Wachter T, et al: Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol 23: 777-790, 2003.
18. Datta SR, Brunet A and Greenberg M: Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927, 1999.
19. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
20. Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257-262, 2003.
21. Dudek H, Datta SR, Franke TF, et al: Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275: 661-665, 1997.
22. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y and Kraft AS: Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276: 10767-10774, 2001.
23. Chen X, Thakkar H, Tyan F, et al: Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073-6083, 2001.
24. Kandasamy K and Srivastava RK: Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 62: 4929-4937, 2002.
25. Panka DJ, Mano T, Suhara T, Walsh K and Mier JW: Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 276: 6893-6896, 2001.
26. Hersey P and Zhang XD: Overcoming resistance of cancer cells to apoptosis. J Cell Physiol 196: 9-18, 2003.
27. Nam SY, Jung GA, Hur GC, et al: Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 94: 1066-1073, 2003.
28. Iwase M, Watanabe H, Kondo G, Ohashi M and Nagumo M: Enhanced susceptibility of oral squamous cell carcinoma cell lines to Fas-mediated apoptosis by cisplatin and 5-fluorouracil. Int J Cancer 106: 619-625, 2003.
29. Kondo G, Iwase M, Watanabe H, et al: Enhancement of susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells by phosphatidylinositol 3-kinase inhibitor. Oral Oncol 42: 745-752, 2006.
30. Lemke LE, Paine-Murrieta GD, Taylor CW and Powis G: Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemother Pharmacol 44: 491-497, 1999.
31. Semba S, Itoh N, Ito M, Harada M and Yamakawa M: The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenylchromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin Cancer Res 8: 1957-1963, 2002.
32. Thakkar H, Chen X, Tyan F, et al: Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. J Biol Chem 276: 38361-38369, 2001.
33. Puduvalli VK, Sampath D, Bruner JM, Nangia J, Xu R and Kyritsis AP: TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10: 233-243, 2005.
34. Chinnaiyan AM, Prasad U, Shankar S, et al: Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 97: 1754-1759, 2000.
35. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK and Huang H: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60: 847-853, 2000.
36. Singh TR, Shankar S, Chen X, Asim M and Srivastava R: Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63: 5390-5400, 2003.
37. Kim JH, Ajaz M, Lokshin A and Lee YJ: Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis. Clin Cancer Res 9: 3134-3141, 2003.
38. Keane MM, Ettenberg SA, Nau MM, Russell EK and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59: 734-741, 1999.
39. Krueger A, Baumann S, Krammer PH and Kirchhoff S: FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21: 8247-8254, 2001. (Pubitemid 33108586)
40. Ryu BK, Lee MG, Chi SG, Kim YW and Park JH: Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol 194: 15-19, 2001.
41. Rippo MR, Moretti S, Vescovi S, et al: FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 24: 7753-7760, 2004. (Pubitemid 39457025)
42. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ and Borden EC: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11: 915-923, 2004.
43. Sharp DA, Lawrence DA and Ashkenazi A: Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 280: 19401-19409, 2005.
44. Kang YC, Kim KM, Lee KS, et al: Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differ 11: 1287-1298, 2004.
45. Kennedy SG, Kandel ES, Cross TK and Hay N: Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 19: 5800-5810, 1999. (Pubitemid 29339934)
46. Ray S, Bucur O and Almasan A: Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 10: 1411-1418, 2005. (Pubitemid 43117685)
47. Salvesen GS and Duckett CS: IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3: 401-410, 2002.
48. Brognard J, Clark AS, Ni Y and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997, 2001. (Pubitemid 32720961)
49. Nakashio A, Fujita N, Rokudai S, Sato S and Tsuruo T: Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 60: 5303-5309, 2000.
50. Tenzer A, Zingg D, Rocha S, et al: The phosphatidylinositol 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res 61: 8203-8210, 2001. (Pubitemid 33091613)
51. Shingu T, Yamada K, Hara N, et al: Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by phosphainositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res 63: 4044-4047, 2003. (Pubitemid 36917925)
52. Hu L, Hofmann J, Lu Y, Mills GB and Jaffe RB: Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087-1092, 2002.
53. Pukac L, Kanakaraj P, Humphreys R, et al: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumor types in vitro and in vivo. Br J Cancer 92: 1430-1441, 2005.
54. Georgakis GV, Li Y, Humphreys R, et al: Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 130: 501-510, 2005.
55. Marini P, Denzinger S, Schiller D, et al: Combined treatment of colorectal tumors with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25: 5145-5154, 2006.
56. Yaguchi S, Fukui Y, Koshimizu I, et al: Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 98: 545-556, 2006.